Compounded tirzepatide had an unusual exit from FDA's shortage list. FDA removed the drug, took the decision back for review after a lawsuit, and then removed it again. Two courts have since upheld that final decision. This guide sets out each step from FDA and court records, checked on November 17, 2026.
Quick answer: Compounded tirzepatide is a prescription drug made by a state-licensed pharmacy or a registered outsourcing facility, and it is not FDA-approved. With the shortage resolved, pharmacies may not make copies of the approved product regularly or in inordinate amounts, and outsourcing facilities may not compound it from bulk tirzepatide. Research-grade tirzepatide is a laboratory reagent for laboratory research use only, not for human or veterinary use.
What is compounded tirzepatide?
The FDA-approved tirzepatide products are Eli Lilly's Mounjaro and Zepbound. Compounded tirzepatide is prepared outside that approval, either by a state-licensed pharmacist or physician under section 503A of the Federal Food, Drug, and Cosmetic Act, or by an FDA-registered outsourcing facility under section 503B.
FDA states that "compounded drugs are not FDA-approved," which means the agency does not verify their safety, effectiveness or quality before they are marketed (FDA, Compounding Q&A). FDA has also stressed that compounded drugs are not generics (FDA, March 3, 2026). Our compounded semaglutide guide explains how the 503A and 503B pathways work in more detail.
How did tirzepatide get on and off the shortage list?
The shortage list matters because several compounding limits relax while a drug is on it. When a drug leaves the list, those limits apply again. Tirzepatide's path off the list took three steps, set out in FDA's December 2024 order (FDA declaratory order).
Tirzepatide shortage, litigation and compounding timeline
| Date | What happened |
|---|---|
| December 15, 2022 | Tirzepatide injection products added to FDA's shortage list |
| October 2, 2024 | FDA finds the shortage resolved and removes tirzepatide from the list |
| October 7, 2024 | Outsourcing Facilities Association and a compounding pharmacy sue FDA in the Northern District of Texas |
| October 11, 2024 | On FDA's motion, the court sends the decision back to FDA to reevaluate |
| December 19, 2024 | FDA issues a new order finding the shortage resolved, replacing the October decision |
| March 5, 2025 | Court denies a preliminary injunction; FDA says the 503A grace period has ended |
| March 19, 2025 | 503B grace period ends |
| April 30, 2026 | FDA proposes keeping tirzepatide off the 503B bulks list |
| August 27, 2026 | Fifth Circuit affirms judgment for FDA and Lilly |
What did FDA decide in December 2024?
The December 19, 2024 order "revokes and replaces" the October decision. FDA concluded that Lilly's supply was "currently meeting or exceeding demand," that Lilly held reserves of finished and semi-finished product, and that it had scheduled substantial additional production. FDA said it also weighed information from patients, health care providers and compounders, and found it had "important limitations."
FDA acknowledged that some people had trouble filling prescriptions. It attributed those problems to the supply chain between Lilly and its customers, such as wholesalers and retailers, not to a national shortage. FDA also noted that a substantial amount of tirzepatide compounding was taking place, and that some of those patients could be expected to move to the approved products.
What may 503A pharmacies and 503B facilities do now?
The December order gave 503A pharmacies until February 18, 2025 and 503B outsourcing facilities until March 19, 2025. FDA later extended each date to the court's ruling on a preliminary injunction, if that came later. The court ruled on March 5, 2025, and FDA then said the 503A period had ended. The 503B period ran to March 19, 2025 (FDA compounding policy page).
FDA restated the rules that apply now on April 1, 2026:
- 503A pharmacies must compound for an individual patient based on a prescription and may not make essentially copies of a commercially available drug "regularly or in inordinate amounts." FDA said it does not intend to act against four or fewer such prescriptions in a calendar month.
- 503B outsourcing facilities generally may compound from a bulk drug substance only if it is on the 503B bulks list or the drug is on the shortage list. FDA stated that tirzepatide is on neither.
FDA has enforced that second point. In an April 7, 2026 warning letter to a registered outsourcing facility, FDA said products it compounded from tirzepatide bulk drug substance were not eligible for the 503B exemptions because "tirzepatide does not appear on the 503B bulks list" and was not used to compound a drug on the shortage list.
On April 30, 2026, FDA proposed not to add tirzepatide, semaglutide or liraglutide to the 503B bulks list (FDA). The Federal Register notice says FDA does not interpret shortages and backorders as a "clinical need" for compounding from bulk. FDA extended the comment period to July 30, 2026. We found no final determination as of November 17, 2026.
What has FDA warned about compounded tirzepatide?
FDA's page on unapproved GLP-1 drugs groups compounded tirzepatide with compounded semaglutide (FDA):
- Dosing errors. FDA has received adverse event reports, some requiring hospitalization, that may relate to dosing errors: patients measuring the wrong amount and, in some cases, clinicians miscalculating. Some reports involved doses beyond the FDA-approved label. FDA says health care providers "should be vigilant when prescribing compounded semaglutide or tirzepatide products."
- Adverse event reports. As of May 31, 2026, FDA had received "more than 730 reports of adverse events associated with compounded tirzepatide," and says such events are likely underreported.
- Marketing. In February 2026, FDA said companies may not present compounded GLP-1 products as generic or the same as approved drugs, and that it intends to restrict GLP-1 active ingredients used in non-approved compounded drugs (FDA, February 6, 2026). In March 2026, it sent 30 warning letters to telehealth companies.
- A later telehealth letter. On October 30, 2026, FDA sent a warning letter to RonanRx, Inc. dba RonanRx (FDA). FDA said the company's website offered compounded semaglutide and tirzepatide products, and that claims on the website and social media were false or misleading under sections 502(a) and 502(bb) of the Act. The letter covers labeling that suggested the company itself compounded the tirzepatide products, claims that implied FDA approval or evaluation, and claims about where the products were made. A warning letter states FDA's view. It is not a court finding.
- U.S. Food and Drug Administration. (2026, October 30). Warning letter: RonanRx, Inc. dba RonanRx, MARCS-CMS 737905. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026
What did the courts decide about tirzepatide?
The compounders argued that FDA should have used notice-and-comment rulemaking and that its shortage decision was arbitrary and capricious. The district court denied a preliminary injunction on March 5, 2025, and an earlier Fifth Circuit panel declined to disturb that ruling. The district court then entered summary judgment for FDA and for Lilly, which had joined the case.
On August 27, 2026, the Fifth Circuit affirmed (No. 25-10600). Assuming without deciding that FDA should have used notice and comment, the court held that the compounders had not shown prejudice. It also found that FDA "engaged in reasoned decision-making" in crediting Lilly's data and explaining why contrary evidence was limited.
What is the status of compounded tirzepatide today?
On November 17, 2026, the record showed:
- Shortage: FDA's database lists tirzepatide injection as "Resolved" (FDA database).
- 503A: no regular copies of the approved product.
- 503B: no compounding from bulk tirzepatide; FDA has proposed keeping it off the bulks list.
- Courts: FDA's decision upheld on appeal.
Shortage status can change, so check FDA's database for the current listing.
Is research-grade tirzepatide the same thing?
No. Research-grade tirzepatide is a laboratory reagent, sold for laboratory research use only, not for human or veterinary use. It is not compounded for a patient, not dispensed on a prescription and not FDA-approved, and it is not an alternative to a prescription medicine.
FDA judges a product by its intended use, shown by objective evidence such as labeling claims, advertising and the circumstances of sale (21 CFR 201.128). In a March 31, 2026 warning letter, FDA said that despite "Research Use Only" labeling, evidence from a seller's website established that its tirzepatide and retatrutide products were "intended to be drugs for human use." FDA has also warned consumers that such products are of unknown quality and may be harmful.
For research background on the compound, see our tirzepatide research guide and what research use only means. For treatment, the route is a licensed prescriber; our page on semaglutide and tirzepatide prescription labels links each FDA label.
Frequently asked questions about compounded tirzepatide
Is compounded tirzepatide legal?
Compounding is legal only within the conditions of section 503A or 503B. Since the shortage ended, 503A pharmacies may not make copies of the approved product regularly or in inordinate amounts, and 503B facilities may not compound from bulk tirzepatide.
Is tirzepatide still in shortage?
No. FDA's final decision that the shortage is resolved dates from December 19, 2024, and its database listed tirzepatide injection as resolved on November 17, 2026.
Why was tirzepatide taken off the shortage list twice?
FDA removed it on October 2, 2024. After compounders sued, FDA asked the court to send the decision back for review, then issued a new order on December 19, 2024 that reached the same result.
Is research-grade tirzepatide compounded tirzepatide?
No. It is a laboratory reagent for laboratory research use only, not for human or veterinary use.
What to know now
- Shortage: listed December 15, 2022; resolved by FDA order December 19, 2024; still resolved on November 17, 2026.
- Grace periods: ended March 2025 for 503A and 503B.
- Rules now: no regular 503A copies; no 503B compounding from bulk tirzepatide.
- FDA warnings: dosing errors, more than 730 adverse event reports as of May 31, 2026, and misleading marketing.
- Courts: Fifth Circuit affirmed for FDA and Lilly on August 27, 2026.
- Research grade: a laboratory reagent, not for human or veterinary use.
What we're watching
FDA's final decision on keeping tirzepatide off the 503B bulks list, how it applies its February 2026 restriction on GLP-1 active ingredients, and any change to the shortage listing.